A. M. Kahveci and V. Tahan, “Daclatasvir plus sofosbuvir regimen sheds promising light on future hepatitis C virus genotype 3 therapies”, Turkish Journal of Gastroenterology, vol. 27, no. 1, pp. 89–90, Jan. 2016.